ArticleCureus2025
Copper/Zinc Ratio as a Predictor of Chronic Kidney Disease Incidence in Type 2 Diabetes: The Asahi Diabetes Complications Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Copper-to-Zinc Ratio and Oxidative Stress Are Associated with Anemia in Older Adults with Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Article
- The interaction between the gene SOD1 rs2070424 and the plasma zinc/copper ratio predicts renal function impairment.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim This study aims to evaluate the associations between the copper/zinc (Cu/Zn) ratio and inflammatory biomarkers and the incidence of chronic kidney disease (CKD) in individuals with type 2 diabetes and to validate our previous cross-sectional study using the baseline data of this study. Methods We conducted a prospective, observational study of 416 individuals with type 2 diabetes without CKD. We used multivariable Cox proportional hazard models to determine the HRs for CKD incidence. The Cu/Zn ratio and soluble tumor necrosis factor-α receptor 1 (sTNFαR1) concentrations (pg/mL) were analyzed as continuous variables and as categories classified according to each cutoff value for detecting CKD. The high-sensitivity C-reactive protein (hsCRP) concentrations between these categories were compared. Results CKD was identified in 165 participants. The Cu/Zn ratio and sTNFαR1 concentrations were identified as significant predictors, independent of each other, after full adjustment (P = 0.048 and P = 0.006, respectively). Compared to the Cu/Zn <1.281 and sTNFαR1 <1081 group, the HRs for the CKD incidence were significantly higher in the Cu/Zn <1.281 and sTNFαR1 ≥1081 group (HR 2.06, 95% CI 1.34-3.26) and even higher in the Cu/Zn ≥1.281 and sTNFαR1 ≥1081 group (3.29, 1.97-5.50) after full adjustment. The hsCRP concentrations were significantly highest in the Cu/Zn ≥1.281 and sTNFαR1 ≥1081 group compared with the other three groups (all P < 0.05) and were significantly higher in the Cu/Zn ≥1.281 and sTNFαR1 <1081 group and in the Cu/Zn <1.281 and sTNFαR1 ≥1081 group compared with those in the Cu/Zn <1.281 and sTNFαR1 <1081 group (both P < 0.05). Conclusions The Cu/Zn ratio and sTNFαR1 concentrations are independent predictors of the incidence of CKD in individuals with type 2 diabetes. Furthermore, under elevated sTNFαR1 concentrations, an increase in the Cu/Zn ratio may further aggravate inflammation and accelerate the incidence of CKD in individuals with type 2 diabetes. These new findings are supported by the results from our previous cross-sectional study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.